ALBANY, N.Y., April 23, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the resumption of shipments of its NanoKnife® System in the U.S. market following a software modification that removed the Ablation Zone Estimator (AZE) feature pursuant to previously announced voluntary actions.
In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
CONTACT: Company Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Greg Gin/Doug Sherk (646) 445-4801; (415) 652-9100 email@example.com; firstname.lastname@example.org Media Contact: EVC Group, Inc. Chris Gale (646) 201-5431 email@example.com